[en] The ketogenic diet is the treatment of GLUT1 deficiency syndrome that provides an alternative energy source for the brain. However, there are some limitations, including compliance issues as well as patients who do not respond to the ketogenic diet. We report the case of two patients that were not on any particular diet. Both experienced infrequent paroxysmal non-epileptic events (acute ataxia and exercise-induced dystonia). Intermittent glucose intake prior to physical activity for exercise-induced symptoms and at the onset of symptoms for acute ataxia showed consistent and reproducible improvement of the symptoms. Our observations raised the question of developing a new treatment strategy with the induction of a sustained increase in blood glucose. For now, the use of this strategy should be limited to a small group of GLUT1-DS patients who are not on a ketogenic diet.
Disciplines :
Pediatrics Neurology
Author, co-author :
Mortaji, Soufiane ; Centre Hospitalier Universitaire de Liège - CHU > > Service de pédiatrie ; AP-HP, Robert-Debré University Hospital, Pediatric Neurology Department, CRMR épilepsies rares, EpiCARE member, Paris, France.
Dozières-Puyravel, Blandine; AP-HP, Robert-Debré University Hospital, Pediatric Neurology Department, CRMR épilepsies rares, EpiCARE member, Paris, France.
Geraldes, Katia; AP-HP, Robert-Debré University Hospital, Pediatric Neurology Department, CRMR épilepsies rares, EpiCARE member, Paris, France.
Perrot, Céline; AP-HP, Robert-Debré University Hospital, Pediatric Neurology Department, CRMR épilepsies rares, EpiCARE member, Paris, France.
Quéméner, Virginie; AP-HP, Robert-Debré University Hospital, Pediatric Neurology Department, CRMR épilepsies rares, EpiCARE member, Paris, France.
Auvin, Stéphane; AP-HP, Robert-Debré University Hospital, Pediatric Neurology Department, CRMR épilepsies rares, EpiCARE member, Paris, France, Université Paris Cité, INSERM NeuroDiderot, Paris, France, Institut Universitaire de France, (IUF), Paris, France. Electronic address: stephane.auvin@aphp.fr.
Language :
English
Title :
Uncommon use of intermittent glucose administration for infrequent non-epileptic paroxysmal events in GLUT1-DS.
Klepper, J., Akman, C., Armeno, M., et al. Glut1 deficiency syndrome (Glut1DS): state of the art in 2020 and recommendations of the international Glut1DS study group. Epilepsia Open 5:3 (2020), 354–365, 10.1002/epi4.12414.
Bekker, Y.A.C., Lambrechts, D.A., Verhoeven, J.S., et al. Failure of ketogenic diet therapy in GLUT1 deficiency syndrome. Eur. J. Paediatr. Neurol. 23:3 (2019), 404–409, 10.1016/j.ejpn.2019.02.012.
Striano, P., Auvin, S., Collins, A., et al. A randomized, double-blind trial of triheptanoin for drug-resistant epilepsy in glucose transporter 1 deficiency syndrome. Epilepsia 63:7 (2022), 1748–1760, 10.1111/epi.17263.
Akman, C.I., Engelstad, K., Hinton, V.J., et al. Acute hyperglycemia produces transient improvement in glucose transporter type 1 deficiency. Ann. Neurol. 67:1 (2010), 31–40, 10.1002/ana.21797.
Ng, B.G., Sosicka, P., Xia, Z., Freeze, H.H., GLUT1 is a highly efficient L-fucose transporter. J. Biol. Chem., 299(1), 2023, 102738, 10.1016/j.jbc.2022.102738.
Choi, I.Y., Lee, S.P., Kim, S.G., et al. In vivo measurements of brain glucose transport using the reversible Michaelis-Menten model and simultaneous measurements of cerebral blood flow changes during hypoglycemia. J. Cerebr. Blood Flow Metabol. 21:6 (2001), 653–663, 10.1097/00004647-200106000-00003.
Duelli, R., Maurer, M.H., Staudt, R., et al. Increased cerebral glucose utilization and decreased glucose transporter Glut1 during chronic hyperglycemia in rat. Brain Res. 858:2 (2000), 338–347, 10.1016/s0006-8993(00)01942-9.
Dozieres-Puyravel, B., Zaman, S., Petrou, S., et al. Usefulness of diagnostic tools in a GLUT1 deficiency syndrome patient with 2 inherited mutations. Brain Dev. 41:9 (2019), 808–811, 10.1016/j.braindev.2019.05.008.
Zaman, S.M., Mullen, S.A., Petrovski, S., et al. Development of a rapid functional assay that predicts GLUT1 disease severity. Neurol.Gene, 4(6), 2018, 10.1212/nxg.0000000000000297.
Kass, H.R., Winesett, S.P., Bessone, S.K., et al. Use of dietary therapies amongst patients with GLUT1 deficiency syndrome. Seizure-Eur. J.Epilep. 35 (2016), 83–87, 10.1016/j.seizure.2016.01.011.
Cappuccio, G., Pinelli, M., Alagia, M., et al. Biochemical phenotyping unravels novel metabolic abnormalities and potential biomarkers associated with treatment of GLUT1 deficiency with ketogenic diet. PLoS One, 12(9), 2017, e0184022, 10.1371/journal.pone.0184022.
Logel, S.N., Connor, E.L., Hsu, D.A., et al. Exploring diazoxide and continuous glucose monitoring as treatment for Glut1 deficiency syndrome. Ann. Clin. Transl. Neurol. 8 (2022), 2205–2209, 10.1002/acn3.51462.
